Page 45 - GPD-1-1

Gene & Protein in Disease Genetically engineered T cells in cancer immunotherapy

94. Narayan V, Barber-Rotenberg JS, Jung IY, et al., 2022, https://doi.org/10.1097/CJI.0b013e3182829903
PSMA-targeting TGFbeta-insensitive armored CAR T cells 103. Linette GP, Stadtmauer EA, Maus MV, et al., 2013,
in metastatic castration-resistant prostate cancer: A phase 1 Cardiovascular toxicity and titin cross-reactivity of affinity-
trial. Nat Med, 28(4): 724–734.
enhanced T cells in myeloma and melanoma. Blood, 122(6):
https://doi.org/10.1038/s41591-022-01726-1 863–871.
95. Rodriguez-Garcia A, Lynn RC, Poussin M, et al., 2021, CAR-T https://doi.org/10.1182/blood-2013-03-490565
cell-mediated depletion of immunosuppressive tumor- 104. Kirtane K, Elmariah H, Chung CH, et al., 2021, Adoptive
associated macrophages promotes endogenous antitumor cellular therapy in solid tumor malignancies: Review of the
immunity and augments adoptive immunotherapy. Nat literature and challenges ahead. J Immunother Cancer, 9(7):
Commun, 12(1): 877.
e002723.
https://doi.org/10.1038/s41467-021-20893-2
https://doi.org/10.1136/jitc-2021-002723
96. Ping Y, Liu C, Zhang Y, 2018, T-cell receptor-engineered 105. Wei F, Cheng XX, Xue JZ, et al., 2022, Emerging strategies in
T cells for cancer treatment: current status and future TCR-engineered T cells. Front Immunol, 13: 850358.
directions. Protein Cell, 9(3): 254–266.
https://doi.org/10.3389/fimmu.2022.850358
https://doi.org/10.1007/s13238-016-0367-1
106. Chandran SS, Klebanoff CA, 2019, T cell receptor-based
97. Zhao Q, Jiang Y, Xiang S, et al., 2021, Engineered TCR-T cell cancer immunotherapy: Emerging efficacy and pathways of
immunotherapy in anticancer precision medicine: Pros and resistance. Immunol Rev, 290(1): 127–147.
cons. Front Immunol, 12: 658753.
https://doi.org/10.1111/imr.12772
https://doi.org/10.3389/fimmu.2021.658753
107. Ahmadzadeh M, Johnson LA, Heemskerk B, et al., 2009,
98. Shafer P, Kelly LM, Hoyos V, 2022, Cancer therapy with Tumor antigen-specific CD8 T cells infiltrating the tumor
TCR-engineered T cells: Current strategies, challenges, and express high levels of PD-1 and are functionally impaired.
prospects. Front Immunol, 13: 835762.
Blood, 114(8): 1537–1544.
https://doi.org/10.3389/fimmu.2022.835762
https://doi.org/10.1182/blood-2008-12-195792
99. Chen X, Wang L, Yue D, et al., 2017, Correlation between the 108. Tokunaga Y, Sasaki T, Goto S, et al., 2022, Enhanced
high expression levels of cancer-germline genes with clinical antitumor responses of tumor antigen-specific TCR T cells
characteristics in esophageal squamous cell carcinoma. genetically engineered to produce IL7 and CCL19. Mol
Histol Histopathol, 32(8): 793–803.
Cancer Ther, 21(1): 138–148.
https://doi.org/10.14670/HH-11-847
https://doi.org/10.1158 / 1535-7163.MCT-21-0400
100. Liu Y, Yan X, Zhang F, et al., 2021, TCR-T immunotherapy: 109. Sailer N, Fetzer I, Salvermoser M, et al., 2022, T-Cells
The challenges and solutions. Front Oncol, 11: 794183.
expressing a highly potent PRAME-specific T-cell receptor
https://doi.org/10.3389/fonc.2021.794183 in combination with a chimeric PD1-41BB co-stimulatory
receptor show a favorable preclinical safety profile and
101. Kageyama S, Ikeda H, Miyahara Y, et al., 2015, Adoptive
transfer of MAGE-A4 T-cell receptor gene-transduced strong anti-tumor reactivity. Cancers (Basel), 14(8): 1998.
lymphocytes in patients with recurrent esophageal cancer. https://doi.org/10.3390/cancers14081998
Clin Cancer Res, 21(10): 2268–2277.
110. Hu Z, Anandappa AJ, Sun J, et al., 2018, A cloning and
https://doi.org/10.1158 / 1078-0432.CCR-14-1559 expression system to probe T-cell receptor specificity and
assess functional avidity to neoantigens. Blood, 132(18):
102. Morgan RA, Chinnasamy N, Abate-Daga D, et al., 2013,
Cancer regression and neurological toxicity following anti- 1911–1921.
MAGE-A3 TCR gene therapy. J Immunother, 36(2): 133–151. https://doi.org/10.1182/blood-2018-04-843763

Volume 1 Issue 1 (2022) 14 https://doi.org/10.36922/gpd.v1i1.114